Abstract 379P
Background
Trastuzumab deruxtecan (T-DXd) has emerged as the standard treatment for patients with metastatic HER2-positive (HER2+) breast cancer (BC) following disease progression on first-line therapy containing taxanes and trastuzumab. Subsequently, results from the DESTINY-Breast04 have extended the approval of T-DXd to include HER2-low patients. Radiation therapy (RT) is often necessary in the metastatic setting, either for palliative purposes or with ablative intent. Our study aims to assess the safety of concurrent use of T-DXd and RT in a consecutive multicentre international cohort of BC patients.
Methods
We conducted a retrospective analysis of patients diagnosed with metastatic HER2+ or HER2-low BC, who were treated at three leading European Institutions. Patients started treatment with T-DXd between May 2021 and March 2024, with some receiving concomitant RT and others not. The primary objective of the study was to assess the association between RT administration and adverse events (AEs) greater than grade (G) 2.
Results
Data of 99 consecutive patients were retrospectively evaluated. Thirty-two patients received RT immediately before (within a month) or during T-DXd, for a total of 33 concomitant RT treatments, while 67 patients did not. Median age was 56 years old (range 34-88). The majority of patients (55.6%) received T-DXd as fourth or further line of systemic therapy. Median total RT dose prescription was 26 Gy (range 8-48) with a median number of fractions of 5 (range 1-15). Median EQD2 dose was 33 Gy (range 12-104) and median BED 39 Gy (14-125). The most frequently treated site was bone (43.8% of patients) followed by brain (37.5%). The relation between RT administration and the development of G2+ toxicity was not significant (p-value = 0.8). Grade 2 interstitial lung disease (IDL), that led to T-DXd discontinuation, was observed in one case in RT group (3.1%) and in three cases in no-RT group (4.5%). No radionecrosis events were observed among the 12 patients treated with intracranial RT.
Conclusions
Our preliminary data are encouraging regarding the potential safety of this combination, showing that concurrent RT did not increase severe acute toxicity.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
394P - Quantitative standardized high sensitivity (HS)-HER2 testing predicts outcomes with trastuzumab deruxtecan (T-DXd) for metastatic breast cancer (MBC)
Presenter: Paolo Tarantino
Session: Poster session 15
395P - Receptor status heterogeneity during metastatic breast cancer treatment
Presenter: Sandra Geurts
Session: Poster session 15
396P - Evaluation of MUC1-C/CD3 biparatopic-bispecific (BPBS) T cell engager as an immunotherapeutic agent for the treatment of MUC1-expressing metastatic breast cancer (mBC)
Presenter: Ravi Jasuja
Session: Poster session 15
397P - Survival of de novo metastatic breast cancer according to biomarker status in Denmark and Norway: A register-based cohort study
Presenter: Johan Liseth Hansen
Session: Poster session 15
398P - Age and ethnic-driven molecular and clinical disparity of East Asian breast cancers
Presenter: Ji Yoon Lee
Session: Poster session 15
399P - Treatment patterns and outcomes in HER2-low, HR+ metastatic breast cancer patients previously treated with endocrine therapy in the United States
Presenter: Shanu Modi
Session: Poster session 15
400P - LncRNA-LINC00294 functions as a ceRNA in regulating JUP through competitively binding to miR-485-5p in breast cancer
Presenter: Ting Yang
Session: Poster session 15
Resources:
Abstract
401P - Evaluation of HER2 scoring in breast carcinoma-stained whole slide images
Presenter: Céline Bossard
Session: Poster session 15
402P - Inflammatory biomarkers for predicting the efficacy of immunotherapy in advanced breast cancer
Presenter: Kuikui Jiang
Session: Poster session 15
403P - Stemness-targeted therapies to inhibit cancer cell plasticity in triple negative breast cancer
Presenter: Andrew Takchi
Session: Poster session 15